Aspirus has successfully completed its first two EVOQUE™ transcatheter tricuspid valve replacement (TTVR) procedures, bringing a new minimally invasive treatment option to patients with severe tricuspid regurgitation, also known as a leaking tricuspid valve.
The procedures were performed May 7, 2026, by Interventional Cardiologists
Colleen Lane, MD, FACC and
Marcus Sublette, MD at Aspirus Wausau Hospital.
The EVOQUE system is a newly approved transcatheter tricuspid valve replacement technology designed to replace the damaged valve through a catheter-based approach, avoiding the need for traditional open-heart surgery. Patients with severe tricuspid regurgitation often experience symptoms such as fatigue, swelling, shortness of breath, and reduced quality of life.
Aspirus is among the first health systems in Wisconsin to offer the procedure. The milestone reflects the advanced capabilities of the Aspirus structural heart program and the high level of trust required to participate in the limited rollout of the technology.
“Historically, many patients with severe tricuspid valve disease were not candidates for surgery because of the high risk associated with traditional procedures,” said Dr. Lane. “For many of these patients, medications were the only option, and they often did not adequately control symptoms. Being able to offer this minimally invasive treatment provides a new, potentially life-saving option for patients in our communities.”
Transcatheter tricuspid valve replacement is performed through a catheter inserted into a blood vessel, allowing physicians to replace the valve without opening the chest. The minimally invasive approach can reduce recovery times and expand treatment options for patients who may not qualify for conventional surgery.
“With an aging population, we are seeing more patients affected by advanced tricuspid valve disease,” said Dr. Sublette. “Until recently, many of these individuals had very limited treatment options beyond medications, which can sometimes carry difficult side effects and may not fully address the disease. This procedure has the potential to significantly improve quality of life for patients who previously had few options available.”
The launch of the EVOQUE program at Aspirus continues the organization’s expansion of advanced cardiovascular services for patients across Wisconsin, the Upper Peninsula of Michigan, and northern Minnesota.
For more information about Aspirus Heart Care, visit
Aspirus Heart & Vascular Services.